A Delaware court has dismissed a case brought by Marstrand Partners, L.P. against Israel Biotech Fund I, L.P. and other defendants, alleging breach of fiduciary duty related to Ayala Pharmaceuticals, Inc. The ruling, issued by Chancellor Kathaleen St. J. McCormick on May 27, 2026, affects shareholders of Ayala Pharmaceuticals and clarifies the standards for derivative lawsuits in Delaware.
The case, Marstrand Partners, L.P. v. Israel Biotech Fund I, L.P., C.A. No. 2024-0421-KSJM, centered around claims that Israel Biotech and its affiliates improperly influenced Ayala's board to approve transactions that were not in the best interest of shareholders. The court's decision underscores the complexities of corporate governance and the challenges shareholders face when pursuing derivative actions.
Background
Marstrand Partners, L.P. is a shareholder of Ayala Pharmaceuticals, Inc., a Delaware corporation focused on developing cancer treatments. The defendants include Israel Biotech Fund I, L.P., Israel Biotech Fund II, L.P., and several individuals associated with these funds. Israel Biotech invested in Ayala in 2017 and played a significant role in the company's leadership, including appointing key executives and board members.
The dispute arose amid Ayala's financial struggles, which included significant losses and threats of delisting from the NASDAQ. In 2022, Ayala announced a merger with Advaxis, Inc., but continued to face difficulties, leading to discussions of further mergers and financing options. The situation escalated with a proposed financing arrangement that Marstrand claimed unfairly benefited the defendants at the expense of other shareholders.
The Ruling
The court ruled in favor of the defendants, granting their motions to dismiss the case. Chancellor McCormick stated, "Because the Complaint fails to satisfy any of the prongs of Zuckerberg’s three-part test, Plaintiff cannot demonstrate that demand is futile as to the Demand Board." This ruling indicates that the plaintiff did not adequately show that the board members were incapable of impartially considering a demand regarding the alleged misconduct.
The court's decision emphasized the importance of the demand futility standard in derivative lawsuits, which requires shareholders to demonstrate that board members cannot independently evaluate a claim against themselves. The court found that the plaintiff's allegations did not meet this standard, particularly regarding the financial interests and independence of the board members involved.
Impact
This ruling has significant implications for shareholders and corporate governance in Delaware. It reinforces the high threshold that plaintiffs must meet to succeed in derivative lawsuits, particularly regarding the demand futility requirement. This decision may discourage future derivative actions unless shareholders can provide more compelling evidence of board misconduct or conflicts of interest.
Moreover, the ruling clarifies the legal standards surrounding the fiduciary duties of directors and the expectations for transparency and accountability in corporate transactions. It highlights the challenges that shareholders face in asserting their rights when corporate boards are perceived to act against their interests.
What's Next
While the court dismissed the case, the decision can potentially be appealed. However, details about any potential appeal or related cases were not available in the court filing. The ruling may also influence how similar cases are approached in the future, as it sets a precedent for the standards of proof required in derivative lawsuits.